Biomatter Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 28

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $7.06M

  • Investors
  • 7

Biomatter General Information

Description

Operator of a synthetic biology company intended to create proteins for health and sustainable manufacturing applications. The company develops ultra-high-throughput data acquisition methods based on synthetic organisms that collect information on different properties of large libraries of proteins, enabling clients to get access to technologies for protein engineering at the intersection of synthetic biology and artificial intelligence.

Contact Information

Website
www.biomatter.ai
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Žirmūnų Street 139A
  • Vilnius, LT-09120
  • Lithuania
+370 (8-614) 00000
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Vertical(s)
Artificial Intelligence & Machine Learning, Life Sciences
Corporate Office
  • Žirmūnų Street 139A
  • Vilnius, LT-09120
  • Lithuania
+370 (8-614) 00000

Biomatter Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biomatter Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Seed Round 05-Aug-2024 $7.06M 00.000 Completed Generating Revenue
3. Seed Round 01-Feb-2023 00000 Completed Generating Revenue
2. Seed Round 11-Jan-2021 $610K $610K Completed Generating Revenue
1. Seed Round Completed Startup
To view Biomatter’s complete valuation and funding history, request access »

Biomatter Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a synthetic biology company intended to create proteins for health and sustainable manufacturing application
Biotechnology
Vilnius, Lithuania
28 As of 2024
00.000
000000000 00.000

000000

lit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim
0000000000000
Eden Prairie, MN
00 As of 0000
000.00
000.00 0000-00-00
000000&0 000.00

00000

nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit
0000000000000
Seattle, WA
00 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Biomatter Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Collagen Solutions Corporate Backed or Acquired Eden Prairie, MN 00 000.00 000000&0 000.00
Cyrus Biotechnology Venture Capital-Backed Seattle, WA 00 000.00 00000000000 000.00
Deep Genomics Venture Capital-Backed Toronto, Canada 000 00000 00000000000 00000
AI Proteins Venture Capital-Backed 00 000.00 00000000000 000.00
Terray Therapeutics Venture Capital-Backed Monrovia, CA 000 000.00 0000000000 0 000.00
You’re viewing 5 of 11 competitors. Get the full list »

Biomatter Patents

  • 10

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 3

    Granted

  • 7

    Pending

  • 000

    Expiring in next 12 mo

Biomatter Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202401559-D0 Synthesis of 1n-methylpseudouridine and 1n-methylpseudouridine phosphates Pending 06-Feb-2024
GB-202203714-D0 Sequence optimization Active 17-Mar-2022 000000000
GB-2616654-A Sequence optimization Active 17-Mar-2022 000000000
GB-2616654-B Sequence optimization Active 17-Mar-2022 000000000
GB-2614570-A C-nucleoside monophosphate synthesis Pending 10-Jan-2022 C12P19/385
To view Biomatter’s complete patent history, request access »

Biomatter Executive Team (6)

Name Title Board Seat
Laurynas Karpus Co-Founder, Chief Executive Officer & Board Member
Donatas Repecka Co-Founder & Co-Chief Technology Officer
Irmantas Rokaitis Co-Chief Technology Officer
Linas Zakrys Chief Scientific Officer
Vykintas Jauniskis Co-Founder, Head of Bioinformatics & Computational Protein Engineer
You’re viewing 5 of 6 executive team members. Get the full list »

Biomatter Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biomatter Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Inventure Venture Capital Minority 000 0000 000000 0
UVC Partners Venture Capital Minority 000 0000 000000 0
Lemonade Stand (Estonia) Venture Capital Minority 000 0000 000000 0
Metaplanet Holdings Venture Capital Minority 000 0000 000000 0
70 Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

Biomatter FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »